Cadrenal Therapeutics, Inc.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$13.2M
- Total assets
- $4.3M
- Market cap
- $13.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $13.5M
- Operating income
- -$13.5M
- Net income
- -$13.2M
- EPS (basic)
- $-6.64
- EPS (diluted)
- $-6.64
Balance sheet
- Total assets
- $4.3M
- Current assets
- $4.3M
- Total liabilities
- $1.6M
- Current liabilities
- $1.6M
- Shareholders’ equity
- $2.7M
Cash flow
- Operating cash flow
- -$12.6M
- Investing cash flow
- -$5.1K
- Financing cash flow
- $6.6M
- Net cash flow
- -$6.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.7M
- EPS (diluted)
- $-6.64
- Shares outstanding
- 3.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 20, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $13.2M.
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cadrenal Therapeutics, Inc..
Write a review
News about Cadrenal Therapeutics, Inc.
News & sentiment via Polygon.io
